ArticleThe Journal of infectious diseases2026
Comparison of Healthcare Resource Utilization and Disease Outcomes in Adults Hospitalized with Human Metapneumovirus and Respiratory Syncytial Virus.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of the Hospital Burden Associated with Respiratory Syncytial Virus and Human Metapneumovirus Across All Age Groups in Scotland: A Retrospective Analysis.Infectious diseases and therapy · 2026Article
- Clinical Outcomes and Molecular Epidemiology of Human Metapneumovirus in Romanian Hospitalized Patients.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundHuman metapneumovirus (hMPV) and respiratory syncytial virus (RSV) are among the leading causes of acute respiratory infection. We evaluated the risk of severe outcomes in adults hospitalized with hMPV compared to RSV at Kaiser Permanente Southern California.
methodsWe performed a retrospective cohort analysis in adults aged ≥18 years who tested positive for hMPV or RSV from 7 days prior to 2 days after the date of hospital admission between 2011 and 2024. Outcomes included length of hospital stay, intensive care unit (ICU) admission, occurrence of complications, readmission, and mortality. Risk ratios (RR) and hazard ratios (HR) were estimated for hMPV compared to RSV hospitalizations.
resultsThis study included 2859 hMPV-associated and 3029 RSV-associated hospitalizations. Approximately 30% of hMPV and RSV hospitalizations had an extended hospital stay (≥7 days) and about 15% were admitted to the ICU. The risk of an extended hospital stay was lower in hMPV than RSV hospitalizations (RR: 0.91 [95% CI: 0.84-0.99]). Over half of hMPV and RSV hospitalizations had pneumonia diagnoses; the risk was higher in hMPV hospitalizations (RR: 1.17 [1.12-1.23]). 1-year mortality risk was lower in hMPV compared to RSV hospitalizations (HR: 0.84 [0.74-0.94]). The risk of most outcomes, including the occurrence of complications, exacerbation of chronic diseases, in-hospital mortality, and readmission was comparable between hMPV and RSV hospitalizations.
conclusionsBoth hMPV and RSV hospitalizations were associated with substantial and similar healthcare resource utilization and morbidity, highlighting the importance of clinical appreciation of severe outcomes associated with hMPV in hospitalized adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.